NMC
PRQR icon

Nine Masts Capital’s ProQR Therapeutics PRQR Stock Holding History

Nine Masts Capital’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$47.8K Buy
+29,518
New +$48.4K 0.01% 144

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Nine Masts Capital's PRQR Position: Q1 2026 in Review

Nine Masts Capital opened a new position in ProQR Therapeutics (PRQR) in Q1 2026: 29,518 shares worth $47.8K. The stake represents 0.01% of the portfolio and ranks #144 among its holdings.

69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

  • Nine Masts Capital held 29,518 shares of ProQR Therapeutics worth $47.8K as of Q1 2026.
  • ProQR Therapeutics was a new Nine Masts Capital position in Q1 2026.
  • ProQR Therapeutics made up 0.01% of Nine Masts Capital's portfolio in Q1 2026, its #144 holding.
  • 69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Nine Masts Capital's 13F filing for Q1 2026, filed 13 May 2026.